Figure 7.

Late DMOG treatment does not inhibit the formation of a Collagen Type II‐rich ECM but does induce a chondrogenic expression profile. (A–G): Collagen Type II immunofluorescence staining at day 21 of chondrogenesis after continuous (days 1–21) and late (days 14–21) CoCl₂, DFX and DMOG treatment (n = 4). Scale bar = 400 μm. Representative images from 4 independent repeats shown. Brightness and contrast were adjusted for all channels to an equal degree between all conditions. (H): Quantification of Collagen Type II immunofluorescence at day 21 of chondrogenic induction, normalized to equivalent DAPI‐immunofluorescence (n = 4). Values are fold change compared with the no‐treatment control represented by the horizontal dotted line. The horizontal, colored lines represent means for each condition. *, p < .05 compared with 20%O₂. (I–L): Gene expression of SOX9 (I), P4HA1 (J), VEGFA (K), and EGLN (L) after continuous (days 1–21) and late (days 14–21) CoCl₂, DFX and DMOG treatment (n = 4). Values are normalized to the housekeeping gene RPL13A and are fold change compared with the no‐treatment control, represented by the horizontal dotted line. The horizontal colored lines represent the means for each condition. *, p < .05 when compared with 20%O₂. Abbreviations: CoCl₂, cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine.